Department of Parasitology and Tropical Medicine, Chonnam National University Medical School, Gwangju, South Korea.
Department of Rheumatology, Hanyang University Institute for Rheumatology Research, Seoul, South Korea.
Front Immunol. 2021 Feb 25;12:615369. doi: 10.3389/fimmu.2021.615369. eCollection 2021.
Helminth infections and their components have been shown to have the potential to modulate and attenuate immune responses. The objective of this study was to evaluate the potential protective effects of -derived protein (CSp) on ankylosing spondylitis (AS). Cytotoxicity of CSp at different doses was assessed by MTS and flow cytometry before performing experiments. Peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear cells (SFMCs) were obtained from AS patients. Inflammatory cytokine-producing cells were analyzed using flow cytometry. The levels of INF- , IL-17A, TNF-α, and IL-6 were measured by enzyme-linked immunosorbent assay (ELISA). SKG mice were treated with CSp or vehicles. Inflammation and new bone formation were evaluated using immunohistochemistry, positron emission tomography (PET), and micro-computed tomography (CT). Treatment with CSp resulted in no reduced cell viability of PBMCs or SFMCs until 24 h. In experiments culturing PBMCs and SFMCs, the frequencies of IFN- and IL-17A producing cells were significantly reduced after CSp treatment. In the SKG mouse model, CSp treatment significantly suppressed arthritis, enthesitis, and enteritis. Micro-CT analysis of hind paw revealed reduced new bone formation in CSp-treated mice than in vehicle-treated mice. We provide the first evidence demonstrating that CSp can ameliorate clinical signs and cytokine derangements in AS. In addition, such CSp treatment could reduce the new bone formation of AS.
寄生虫感染及其成分已被证明具有调节和减弱免疫反应的潜力。本研究的目的是评估 - 衍生蛋白 (CSp) 对强直性脊柱炎 (AS) 的潜在保护作用。在进行实验之前，通过 MTS 和流式细胞术评估 CSp 在不同剂量下的细胞毒性。从 AS 患者中获得外周血单核细胞 (PBMC) 和滑液单核细胞 (SFMC)。使用流式细胞术分析产生炎性细胞因子的细胞。通过酶联免疫吸附试验 (ELISA) 测量 INF- 、IL-17A、TNF-α 和 IL-6 的水平。用 CSp 或载体处理 SKG 小鼠。通过免疫组织化学、正电子发射断层扫描 (PET) 和微计算机断层扫描 (CT) 评估炎症和新骨形成。CSp 治疗不会降低 PBMC 或 SFMC 的细胞活力，直到 24 小时。在培养 PBMC 和 SFMC 的实验中，CSp 处理后 IFN- 和 IL-17A 产生细胞的频率明显降低。在 SKG 小鼠模型中，CSp 治疗显著抑制关节炎、肌腱炎和肠炎。后爪的 micro-CT 分析显示，CSp 治疗组小鼠的新骨形成明显低于载体治疗组小鼠。我们提供了第一个证据，证明 CSp 可以改善 AS 的临床症状和细胞因子紊乱。此外，CSp 治疗可以减少 AS 的新骨形成。
